QVM149
Investigational Novartis therapy smashes primary and secondary endpoints in uncontrolled asthma
May 30, 2019Research and Development Novartis, QVM149, asthma, pharma
Novartis has announced the first findings on the efficacy of its investigational asthma therapy QVM149 in the treatment of inadequately …
Latest content
Highlighting the value of lab research for healthcare innovation
November 2, 2026
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
